2023

Our OctoPatch® technology was selected in the top 20 of the DCB Innovation Challenge in the category of Diabetes Devices. This global challenge gathers ideas that could facilitate the management of diabetes and improve the quality of life of affected patients. The selected teams get access to the DCB’s network of industry experts, coaching sessions and trainings. Diabetes Center Berne (DCB) is a private, independent Swiss foundation focused on the identification and translation of ideas into products that can make life with diabetes easier.

Read the announcement at https://www.dcberne.com/en/dcb-innovation-challenge-meet-the-top-20-diabetes-devices/. Learn more about the DCB at https://www.dcberne.com/en/.

Transire Bio was selected in the top 10 of W.A. De Vigier Award − Switzerland’s oldest award for young entrepreneurs and one of the most prestigious ones. A three-stage selection process evaluates the entrepreneurial personality along with the innovation, social impact, technical and financial aspects and market potential of the proposed project. We are honored to be selected in this year’s top 10 and we are looking forward to giving our final pitch this May in Solothurn.

Read the full press release at https://devigier.ch/press-release-top-10-2023/. Learn more about Bil De Vigier and W.A. De Vigier Foundation at https://devigier.ch/.

Transire Bio represented by our co-founder David Klein Cerrejon wins polyPITCH 2023! polyPITCH is a competition for scientific staff at ETH Zurich working on innovative projects with commercial potential. The participants pitch to the selected members of the Swiss startup community and the winner is awarded with a monetary prize.

Learn more about the polyPITCH at https://polypitch.ch/.

Transire Bio is selected in the top 15 of W.A. De Vigier Award! The next selection stage will involve evaluating business plans by the foundation’s experts and the new round of pitching to the foundation’s board in April.

Read the full press release at https://devigier.ch/press-release-top-15-2023/. Learn more about Bil De Vigier and W.A. De Vigier Foundation at https://devigier.ch/.

We are honored to have given our first official pitch with Transire Bio at the top 50 of W.A. De Vigier Award. We were selected among 310 applicants and we will have a chance to pitch in Soloturn in the Life Sciences & Biotech & Pharma cluster.

Read the press release at https://devigier.ch/press-release-selection-day-top50-2023/. Learn more about Bil De Vigier and W.A. De Vigier Foundation at https://devigier.ch/.

Transire Bio was selected to participate at SPARK Night Zurich. Our co-founders David and Nevena presented our technology and discussed open questions with the selected group of experts, investors and fellow entrepreneurs. SPARK Zurich provides a mentoring network for researchers with biotech projects. It is based on the SPARK program developed at Stanford University, which substantially increases the translational success rate of the ideas coming from academia.

Learn more about the Spark Night Zurich at https://www.sparkzurich.ch/.